Human p53264-272 HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice

Cancer Letters

Volumn 137, Issue 2, 1999, Pages 183-191

  Petersen, Troels R ^a   Bregenholta, Søren ^a   Pedersen, Lars Ø ^a   Nissen, Mogens H ^a   Claesson, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CTL; DNA immunization; MHC I; p53

Indexed keywords

CARDIOTOXIN; DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; PROTEIN P53; SNAKE VENOM; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE EXPRESSION; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; CELL STRAIN COS1; CELLULAR IMMUNITY; CYTOLOGY; CYTOTOXICITY TEST; DENDRITIC CELL; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; COS CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; GENE EXPRESSION; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VACCINES, DNA;

EID: 0032588228     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00353-X     Document Type: Article

References (33)

1. Hollstein M., Sidranskv D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
2. Lane D.P., Benchimol S. p53: oncogene or anti-oncogene. Genes Dev. 4:1990;1-8.
3. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
4. Germain R.N. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell. 76:1994;287-299.
5. Houbiers J.G., Nijman H.W., Van Der Burg S., Drijfhout J.W., Kenemans P., van de Velde C.J., Brand A., Momburg F., Kast W.M., Melief C.J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:1993;2072-2077.
6. Röpke M., Regner M., Claesson M.H. T cell-mediated cytotoxicity against p53 protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol. 42:1995;98-103.
7. Vennegoor C.J., Nijman H.W., Drijfhout J.W., Vernie L., Verstraeten R.A., von Mensdorff-Pouilly S., Hilgers J., Verheijen R.H., Kast W.M., Melief C.J., Kenemans P. Autoantibodies to p53 in ovarian cancer patients and healthy women: A comparison between whole p53 protein and 18-mere peptides for screening purpose. Cancer Lett. 116:1997;93-101.
8. Regner M., Claesson M.H., Bregenholt S., Röpke M. An improved method for detection of peptide-induced upregulation of HLA-A2 molecules on TAP deficient T2 cells. Exp. Clin. Immunogenet. 13:1996;30-35.
9. Röpke M., Hald J., Guldberg P., Zeuthen J., Nørgaard L., Fugger L., Svejgaard A., Van Der Burg S., Nijman H.W., Melief C.M.J., Claesson M.H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA. 93:1996;14704-14707.
10. Liu M.A. Overview of DNA vaccines. Ann. N.Y. Acad. Sci. 772:1995;15-20.
11. Ertl H.C.J., Verma P., He Z., Xiang Z.Q. Plasmid vectors as anti-viral vaccines. Ann. N.Y. Acad. Sci. 772:1995;77-87.
12. Hofman L.S., Dolland D.L., Sedegah M., Gramzinski R., Wang H., Gowda K., Hobart P., Margalith M., Norman J., Hedstrom R.C. Nucleic acid malaria vaccines: Current status and potential. Ann. N.Y. Acad. Sci. 772:1995;88-94.
13. Hsu C.-H., Chua K.-Y., Tao M.-H., Lia Y.-L., Wu H.-D., Huang S.-H., Hsieh K.-H. lmmunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nature Med. 2:1996;540-544.
14. Corr M., Lee D.J., Carson D.A., Tighe H. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. 184:1996;1555-1559.
15. Schirmbeck R., Bohm W., Ando K., Chisari F.V., Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69:1995;5929-5934.
16. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1991;1007-1015.
17. Salter R.D., Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5:1986;943-949.
18. Baker S.J., Markowitz S., Fearon E.R., Willson J.K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:1990;912-915.
19. Hald J., Rasmussen N., Claesson M.H. Tumor infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol. Immunother. 41:1995;243-250.
20. Jaattela M., Wissing D. Heat-shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection. J. Exp. Med. 177:1993;231-236.
21. Bregenholt S., Röpke M., Skov S., Claesson M.H. Ligation of MHC class I molecules on peripheral blood T lymphocytes induces new phenotypes and functions. J. Immunol. 157:1996;993-999.
22. Davis H.L., Schirmbeck R., Reimann J., Whalen R.G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum. Gene Ther. 6:1995;1447-1456.
23. Theobald M., Biggs J., Dittmer D., Levine A.J., Sherman L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA. 92:1995;11993-11997.
24. Theobald M., Biggs J., Hernandez J., Lustgarten J., Labadie C., Sherman L.A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:1997;833-841.
25. Vierboom M.P., Nijman H.W., Offringa R., van der Voort E.I., van H.T., van D.B., Fleuren G.J., Kenemans P., Kast W.M., Melief C.J. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:1997;695-704.
26. Yu Z., Liu X., McCarty T.M., Diamond D.J., Ellenhorn J.D. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J. Surg. Res. 69:1997;337-343.
27. Soussi T., Caron D.F., Mechali M., May P., Kress M. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene. 1:1987;71-78.
28. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptics eluted from MHC molecules. Nature. 351:1991;290-296.
29. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 74:1993;929-937.
30. Nijman H.W., Van Der Burg S., Vierboom M.P., Houbiers J.G., Kast W.M., Melief C.J. p53, a potential target for tumor-directed T cells. Immunol. Lett. 40:1994;171-178.
31. Gao G.F., Tormo J., Gerth U.C., Wyer J.R., McMichael A.J., Stuart D.I., Bell J.I., Jones E.Y., Jakobsen B.K. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature. 387:1997;630-634.
32. Tanabe M., Minami M., Kano K., Takiguchi M. The allorecognition of H-2Kb-specific CD4-CD8- T cell hybridomas is influenced by the substitution at residue 256 of MHC class I molecules. J. Immunol. 145:1990;1968-1973.
33. Yamamoto J., Tanabe M., Minami M., Kano K., Takiguchi M. Allo-class I-reactive CD4-CD8- T cell hybridomas recognize the conformational change of class I molecule resulting from the exchange of the alpha 3 domain. Eur J. Immunol. 19:1989;1861-1865.